Skip to main content

Lab Notes: Adaptimmune to expand manufacturing at Navy Yard; Helius raises $18M with stock sale

A Philadelphia biotechnology company gets orphan drug status for its new drug candidate.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.